Form 8-K Mersana Therapeutics, For: Jan 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mersana (MRSN) Defended at Cowen
January 5, 2021 12:49 PM ESTCowen analyst Boris Peaker defended Mersana (NASDAQ: MRSN) after the company presented XMT-1536 ovarian data in 18 addt'l pts (n=47) and announced a single-arm registrational trial per FDA feedback to start in 1Q21.
"In NaPi2b-high, ORR was 32% w/ mDOR of ~5 mos.... More
